Stoke Therapeutics, Inc.
NASDAQStoke Therapeutics heads into its August 7 earnings print as one of the more heavily shorted small-cap biotechs in the RNA medicine space, with positioning that has shifted sharply more bearish over the past month. Short sellers have been building aggressively. Short interest has climbed to 27.5% of the free float — up 33% in a month and nearly 14% in the last week alone, with the…
Snapshot as of 4 Aug 2026
Stoke Therapeutics heads into its August 7 earnings print as one of the more heavily shorted small-cap biotechs in the RNA medicine space, with positioning that has shifted sharply more bearish over the past…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for STOK — free to start on ORTEX.
Sign up for free →Open STOK on ORTEX